SOURCE: Vicor Technologies, Inc.

Vicor Technologies, Inc.

February 23, 2010 08:30 ET

Vicor Technologies Announces Extensive Collaborative Agreement With the Universidad San Francisco de Quito in Ecuador

BOCA RATON, FL--(Marketwire - February 23, 2010) - David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that the Company has entered into a collaborative agreement with the Universidad San Francisco de Quito in Ecuador to further awareness and use of the measure of heart rate variability as a medical diagnostic. Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i® nonlinear algorithm and software to stratify patients at risk of sudden cardiac death and autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.

Vicor's PD2i Analyzer™ displays and analyzes electrocardiographic data to provide a measure of heart rate variability (HRV) in patients at rest, and during controlled exercise and paced respiration. The clinical significance of HRV is physician determined. Under the terms of the agreement Vicor will collaborate with the Universidad San Francisco de Quito (USFQ) to:

--  develop academic programs that advance awareness and use of the measure
    of heart rate variability (HRV) to diagnose various medical disorders
    within a variety of health-challenged and/or at risk populations,
--  promote continued research into the uses of HRV in USFQ clinics, and
--  stimulate assistance from Ecuador's public and private health sectors
    with the goal of preventing disease with appropriate
    intervention/treatment based on early diagnosis using HRV.

Additionally, Vicor will serve as the sponsor of the Vicor Technologies, Inc. Heart Rate Variability Institute at the Universidad San Francisco de Quito, with the express purpose of furthering throughout Ecuador HRV research and its use as a medical diagnostic as measured with Vicor's PD2i Analyzer™.

Specifically, this collaboration will involve the Inclusion Institute, its emergency rooms, and intensive care units for applications involving patients at imminent risk of death, those with severe psychiatric illness, and those with elevated cardiovascular risk and mental illness.

This effort may also include study of HRV as measured by Vicor's PD2i Analyzer™ to identify autonomic nervous system dysfunction in diabetics, the need for lifesaving intervention in trauma victims as a means of facilitating triage efforts, imminent mortality in those with brain injury, and the risk of sudden cardiac death in target populations, including young athletes.

"Science and technology have propelled knowledge and practical applications in medicine at a fantastic speed. The collaboration of several universities for the purpose of investigating the risk of sudden death in certain special groups will definitely broaden the spectrum of routine procedures that will result in the prevention of these events and the salvage of precious human lives," stated Dr. Enrique Noboa, Dean, USFQ School of Medicine.

"Autonomic nervous system dysfunction and its role in disease constitute a field of continuous expansion and research. The implications of heart rate variability analysis involve several disciplines, and focus our attention in multi-causality. Furthermore, the rapid, precise, non-invasive and cost-effective stratification of risk of AD in patients admitted to the Emergency Department with the PD2i® test is invaluable. I welcome Vicor's initiative involving the identification of autonomic nervous system dysfunction, and the research and application of heart rate variability analysis, as important components in the promotion of health, prevention of disease, and as a means of providing immediate response and intervention in life threatening scenarios," stated Dr. Michelle Grunauer, Project Manager, USFQ HRV Institute.

"We are extremely pleased and honored to be selected for such a significant collaboration with the Universidad San Francisco de Quito, a private university with a first class international reputation that attracts outstanding educators. We're especially excited about furthering awareness of the measure of HRV as a diagnostic in general, and for identifying autonomic nervous system dysfunction, trauma severity, and the risk of sudden cardiac death. Most importantly, USFQ has two campuses and research facilities, as well as clinics throughout Ecuador, which will enable the outcomes of our collaborative efforts to benefit Ecuadorians throughout the country," stated Mr. Fater.

The Universidad San Francisco de Quito is a non-profit liberal arts university. Founded in 1988 by the Corporación de Promoción Universitaria, (its umbrella non-profit foundation), the USFQ was the first totally private, self-financed university in Ecuador. Today, the USFQ has sixteen Colleges and Academic Institutes spread across its main campus in Cumbayá-Quito and The Galapagos Academic Institute for the Arts and Sciences in San Cristobal in the Galapagos Archipelago. Additionally, USFQ has a biodiversity research station in Tiputini and an anthropology research institute in Riobamba.

About Vicor Technologies, Inc.

Vicor Technologies is a biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i®). The PD2i® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

Vicor currently has three products employing the PD2i® nonlinear algorithm. The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability; physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of sudden cardiac death.

Vicor anticipates additional applications employing the PD2i® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense or the U.S. Government of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements

Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to obtain FDA approval of the PD2i VS™ (Vital Sign) for military and civilian applications and the PD2i CA™(Cardiac Analyzer), our ability to continue to receive financing sufficient to continue operations and complete the critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies, included but not limited to our ASP distribution model for the PD2i Analyzer™; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 10-03

Contact Information